Should reperfusion strategies in myocardial infarction be modified for the very elderly?

American Heart Journal

Volumn 143, Issue 3, 2002, Pages 373-376

  Kroll, Christopher R ^a   Ohman, E Magnus ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; AGED; CLINICAL TRIAL; EDITORIAL; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; LIFE EXPECTANCY; MEDICAL LITERATURE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURGICAL RISK; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036188742     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.120779     Document Type: Article

References (36)

1. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999
2. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials)
3. Trends in acute myocardial infarction and coronary heart disease in the United States
4. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Colaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
5. Thrombolytic therapy in the elderly
6. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
7. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction
8. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: ASSENT-2 double-blind randomized trial. Assessment of the safety and efficacy of new thrombolytic investigators
9. The global use of strategies to open occluded coronary arteries (GÚSTO III) investigators: A comparison of releplase with alteplase for acute myocardial infarction
10. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-1 trial. Global utilization of streptokinase and tPA for occluded coronary arteries trial
11. Comparison of primary coronary angioplasty with tissue intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
12. Lessons from the pooled outcome of the PAMI, ZWOLLE, and Mayo Clinic randomized trials of primary angioplasty versus thrombolytic therapy of acute myocardial infarction
13. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients
14. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction
15. Effects of coronary stenting on restenosis and occlusion after angioplasty of the culprit vessel in patients with recent myocardial infarction
16. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction
17. Coronary angioplasty with or without stent implantation for acute myocardial infarction
18. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heporin during percutaneous coronary revascularization
19. Randomized placebo controlled and balloon ongioplasty controlled trial to assess safety of platelet glycoprotein-IIb/IIIa blockade
20. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
21. One-year survival following early revascularization from cardiogenic shock
22. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome; overall findings of the SHOCK trial registry
23. Morbidity and mortality rates in elderly patients undergoing percutaneous transluminal angioplasty
24. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
25. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular enlargement trial
26. GISSI-3: 4 Year follow-up
27. Which patient benefits from early ACE inhibition after myocardial infarction? Results of the 1-year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS)
28. Early vs delayed ACE inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial
29. Randomized, placebo controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
30. Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure
31. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The RESOLVD Pilot Study
32. Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of people
33. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction